18
What percentage of people with type 2 diabetes have cardiorenal complications?
60
What are the key metabolic risks?
120
What role do SGLT2 inhibitors and GLP-1 receptor agonists have to play?
202
How many people who need these agents receive them?
263
What needs to change to fully mitigate cardiorenal risks?
17
Is there a perception that diabetes care is not the responsibility of cardiologists?
93
What is the link between diabetes and cardiovascular outcomes?
185
What have we learnt from the cardiovascular outcomes trials with SGLT2 inhibitors and GLP-1 receptor agonists?
717
What role could these agents play in the inpatient cardiovascular care setting?
19
What did you hope to show with the TrialNet study?
71
Have there been any surprises in the results?
203
How can this information shape future treatment options for type 1 diabetes?
18
What are incretins, and are they a new concept?
159
How do incretins stimulate insulin secretion?
310
How do the hormones GLP-1 and GIP interact?
512
How can broader understanding of the incretin story drive the development of novel therapies?
17
What is the problem your project aimed to address?
64
Can you provide an overview of your project and some main findings?
167
How does income and immigration status affect people’s ability to manage their diabetes?
235
How can social media help?
416
What new features would you like to see developed?
16
What is the definition of youth-onset type 2 diabetes?
62
What are the unique challenges of youth-onset type 2 diabetes?
213
Is there a genetic picture emerging?
328
What are the biological insights provided by genetic studies on youth-onset diabetes?
472
How can this emerging genetic information shape future management?
18
What are the links between vascular stiffness and type 2 diabetes?
41
Are we seeing these changes at a younger age?
79
How was the TODAY study conducted?
120
What was the most important result – and was it what you expected?
157
How will the results of TODAY affect treatment decisions for people with type 2 diabetes?
18
How do diabetes rates in children and young people compare with those from 10 or 20 years ago?
120
What is driving the changes that we are seeing?
208
What are your projections for the diabetes burden in the US over the next 40 years?
453
How can we tackle this?
In collaboration with
